These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21365202)

  • 21. The nosology of tardive syndromes.
    Frei K; Truong DD; Fahn S; Jankovic J; Hauser RA
    J Neurol Sci; 2018 Jun; 389():10-16. PubMed ID: 29433810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Strategies for Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31880872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of tardive dyskinesia and tardive dystonia.
    Simpson GM
    J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of tardive dyskinesia.
    Egan MF; Apud J; Wyatt RJ
    Schizophr Bull; 1997; 23(4):583-609. PubMed ID: 9365997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse of tardive dyskinesia due to reduction in clozapine dose.
    Shrivastava M; Solanke B; Dakhale G; Somani A; Waradkar P
    Indian J Pharmacol; 2009 Aug; 41(4):201-2. PubMed ID: 20523875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.
    Bergman H; Walker DM; Nikolakopoulou A; Soares-Weiser K; Adams CE
    Health Technol Assess; 2017 Aug; 21(43):1-218. PubMed ID: 28812541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Bhidayasiri R; Fahn S; Weiner WJ; Gronseth GS; Sullivan KL; Zesiewicz TA;
    Neurology; 2013 Jul; 81(5):463-9. PubMed ID: 23897874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Historical perspectives on tardive dyskinesia.
    Caroff SN; Ungvari GS; Cunningham Owens DG
    J Neurol Sci; 2018 Jun; 389():4-9. PubMed ID: 29454494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistent tardive dyskinesia and parkinsonism.
    Jankovic J; Casabona J
    Clin Neuropharmacol; 1987 Dec; 10(6):511-21. PubMed ID: 2892586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Setting the record straight: The nosology of tardive syndromes.
    Truong DD; Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():146-150. PubMed ID: 30528171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia.
    Clyne KE; Juhl R
    Am J Hosp Pharm; 1976 May; 33(5):481-6. PubMed ID: 1274963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive dyskinesia and atypical antipsychotic drugs.
    Casey DE
    Schizophr Res; 1999 Mar; 35 Suppl():S61-6. PubMed ID: 10190226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.